Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
1.
Article | IMSEAR | ID: sea-220313

ABSTRACT

Aim: The aim of this study was to evaluate the anti-hypertensive efficacy of a fixed-dose combination (FDC) of Efonidipine 40 mg and Telmisartan 40 mg in Stage II hypertensive patients. Study Design: Multicentric, randomized, double-blind, parallel, comparative Phase III clinical trial. Methodology: This clinical trial was conducted at six geographically distributed sites across India and enrolled 240 Stage II hypertensive patients. They were randomized into two groups in a ratio of 1:1 using computer-generated block randomization to receive E+T (FDC of Efonidipine 40 mg + Telmisartan 40mg) or C+T (FDC of Cilnidipine 10 mg + Telmisartan 40 mg) group intervention once daily for a period of 90 days. The study site staff, investigator and patients were blinded to the treatment allocation. The primary endpoint of the study evaluated the mean reduction in sitting systolic BP (SBP) and diastolic BP (DBP) from baseline to day 90 whereas the secondary endpoints assessed were mean reduction in BP from baseline to day 30 & 60, patients achieving target BP (<140/90 mmHg) and the safety and tolerability of the investigational products based on the incidences of adverse events (AEs) reported. Results: A total of 118 subjects were randomized to the E+T group wherein the mean (±SD) SBP and DBP at baseline was 167.25 ± 4.68/107.26 ± 5.19 mmHg. After 30 days of treatment with the E+T group, the mean reduction in SBP/DBP of 29.37/18.06 mmHg was observed whereas at Day 60 reduction of 38.55/22.69 mmHg was seen from the baseline. At Day 90, SBP/DBP decreased to 119.41±14.99/81.67±4.29 mmHg with a mean reduction of 47.94/25.89 mmHg in the E+T group. During the study period, the difference in systolic blood pressure between the treatments with E+T and C+T was -0.48 mmHg, with the two-sided 95% confidence interval (CI) ranging from -4.54 to 3.58?mmHg. The corresponding difference in diastolic blood pressure was -0.77 (95% CI: -2.60 to 1.06) mm?Hg. The upper boundary of the 95% CI was below the margin of 10?mmHg, confirming the non-inferiority of E+T to C+T. A total of 92% of patients who had been assigned to E+T treatment achieved their target BP goal. Only one patient reported an adverse event with E+T treatment. No unexpected AEs were reported in the E+T group suggesting its good safety and tolerability. Overall, the E+T treatment was effective, safe and well-tolerated by the patients for 90 days. Conclusion: It was concluded that the FDC of Efonidipine 40 mg and Telmisartan 40 mg was efficacious in the management of Stage II hypertension.

2.
Article | IMSEAR | ID: sea-223678

ABSTRACT

Background & objectives: In clinical settings, peripheral blood pressure (PBP) is measured routinely. It is thought that central blood pressure (CBP) which reflects aortic BP, may be more predictive of outcomes in specific populations. Hence, this study was carried out to measure CBP in patients with hypertension and to see the effect of antihypertensive drugs on CBP. Methods: This cross-sectional study was conducted on 134 hypertensive patients and 134 normotensive healthy individuals as controls. Peripheral BPs and CBPs were measured of all patients and controls. The data were correlated and the effect of antihypertensive drugs on CBP was also evaluated. Results: Of the 134 hypertensive patients, 44 (32.84%) were newly diagnosed and the rest 90 (67.16%) had a history of hypertension and were on treatment. Of these 90 patients on treatment, 37 (41.11%) had uncontrolled peripheral BP and 53 (58.89%) had normal peripheral BP. Of the 134 hypertensive patients, 45 (33.58%) had controlled CBP. In 90 patients, who were on antihypertensive treatment, 45 (50%) had controlled CBP and 45 (50%) had uncontrolled CBP. Patients on calcium channel blockers (CCBs) had better control of CBP. Interpretation & conclusions: Hypertension is diagnosed mainly by measuring peripheral BP. CBP, which correlates better with the incidence of cardiovascular events, is not routinely measured. Patients with a history of hypertension and on treatment had normal office peripheral BP, but a few of them had high CBP and may require modification in treatment for control of CBP. Control of CBP was better in patients taking CCB.

3.
Journal of Rural Medicine ; : 33-39, 2022.
Article in English | WPRIM | ID: wpr-913203

ABSTRACT

Objective: Nitroglycerin is a first-line treatment for hypertensive acute heart failure syndrome (AHFS). However, nicardipine is frequently used to treat hypertensive emergencies, including AHFS. In this study, we compared the effectiveness of nicardipine and nitroglycerin in patients with hypertensive AHFS.Patients and Methods: This single-center, retrospective, observational study was conducted at the intensive care unit of a Japanese hospital. Patients diagnosed with AHFS and systolic blood pressure 140 mmHg on arrival between April 2013 and March 2021 were included. The outcomes were the time to optimal blood pressure control, duration of continuous infusion of antihypertensive agents, duration of positive pressure ventilation, need for additional antihypertensive agents, length of hospital stay, and body weight changes. Outcomes were compared between the nicardipine and nitroglycerin groups. We also compared these outcomes between the groups after excluding patients who received renal replacement therapy.Results: Fifty-eight patients were enrolled (26 and 32 patients were treated with nitroglycerin and nicardipine, respectively). The nicardipine group had a shorter time to optimal blood pressure control (2.0 [interquartile range, 2.0–8.5] h vs. 1.0 [0.5–2.0] h), shorter duration of continuous anti-hypertensive agent infusion (3.0 [2.0–5.0] days vs. 2.0 [1.0–2.0] days), less frequent need for additional anti-hypertensive agents (1 patients [3.1%] vs. 11 patients [42.3%]), and shorter length of hospital stay (17.5 [10.0–33.0] days vs. 9.0 [5.0–15.0] days) than the nitroglycerin group. The duration of positive pressure ventilation and body weight changes were similar between the groups. The outcomes were similar after excluding patients who received renal replacement therapy.Conclusion: Nicardipine may be more effective than nitroglycerin for treating hypertensive AHFS.

4.
Asian Pacific Journal of Tropical Biomedicine ; (12): 214-221, 2021.
Article in Chinese | WPRIM | ID: wpr-950249

ABSTRACT

Objective: To investigate the pharmacological potential of Argemone mexicana in treating constipation and emesis by using in vitro and in vivo models. Methods: The spasmogenic and spasmolytic effects were evaluated on isolated rabbit jejunum fragments loaded in a tissue organ bath. The response was recorded with an isotonic transducer attached with Power Lab Data Acquisition System. The laxative and antiemetic activities were assessed in BALB-c mice and poultry chicks challenged with carbamylcholine and copper sulphate stimulated emesis, respectively. Results: The total phenolic and total flavonoids contents of the extract were (267.75 ± 5.77) mg GAE/g and (73.86 ± 6.01) mg QE/g, respectively. Argemone mexicana extract exerted spasmogenic effect on isolated rabbit jejunum segments with an EC50 value of 0.016 mg/mL, which was blocked by atropine (0.3 μM). Argemone mexicana extract exerted spasmolytic effect in atropine treated jejunum fragments with an EC50 value of 2.185 mg/mL. Furthermore, Argemone mexicana extract relaxed potassium (80 mM)-induced contractions (EC50: 9.07 mg/mL), similar to a standard drug verapamil. The calcium channel blocker activity was confirmed by a rightward shift of concentration-response curve of calcium in the presence of Argemone mexicana extract (1-5 mg/mL) and verapamil (0.1-1 μM). In addition, the extract increased the distance travelled by a charcoal in the gastrointestinal tract and exhibited antiemetic effect on copper sulphate induced emesis in chicks. Conclusions: Argemone mexicana shows cholinergic agonist and calcium channel blocker activities, as well as antiemetic effect. It may be used as a potential agent for treating gastrointestinal disorders.

5.
Asian Pacific Journal of Tropical Biomedicine ; (12): 214-221, 2021.
Article in Chinese | WPRIM | ID: wpr-883382

ABSTRACT

Objective: To investigate the pharmacological potential of Argemone mexicana in treating constipation and emesis by using in vitro and in vivo models.Methods: The spasmogenic and spasmolytic effects were evaluated on isolated rabbit jejunum fragments loaded in a tissue organ bath. The response was recorded with an isotonic transducer attached with Power Lab Data Acquisition System. The laxative and antiemetic activities were assessed in BALB-c mice and poultry chicks challenged with carbamylcholine and copper sulphate stimulated emesis, respectively. Results: The total phenolic and total flavonoids contents of the extract were (267.75 ± 5.77) mg GAE/g and (73.86 ± 6.01) mg QE/g, respectively. Argemone mexicana extract exerted spasmogenic effect on isolated rabbit jejunum segments with an EC50 value of 0.016 mg/mL, which was blocked by atropine (0.3 μM). Argemone mexicana extract exerted spasmolytic effect in atropine treated jejunum fragments with an EC50 value of 2.185 mg/mL. Furthermore, Argemone mexicana extract relaxed potassium (80 mM)-induced contractions (EC50: 9.07 mg/mL), similar to a standard drug verapamil. The calcium channel blocker activity was confirmed by a rightward shift of concentration-response curve of calcium in the presence of Argemone mexicana extract (1-5 mg/mL) and verapamil (0.1-1 μM). In addition, the extract increased the distance travelled by a charcoal in the gastrointestinal tract and exhibited antiemetic effect on copper sulphate induced emesis in chicks. Conclusions: Argemone mexicana shows cholinergic agonist and calcium channel blocker activities, as well as antiemetic effect. It may be used as a potential agent for treating gastrointestinal disorders.

6.
Article | IMSEAR | ID: sea-215112

ABSTRACT

Gingival enlargement is a complication associated with certain drugs (antihypertensives, anticonvulsants, and immunosuppressants). Amlodipine is a calcium antagonist and is structurally similar to nifedipine but pharmacodynamically different from it. The prevalence of amlodipine induced gingival enlargement is reported to be 3.3% which is lower than other calcium channel blockers. We wanted to determine the prevalence of amlodipine (calcium channel blocker) mediated gingival enlargement in patients undergoing treatment for hypertension for more than 6 months and explore how the patients' age, gender, treatment duration, and oral hygiene are related to gingival enlargement. METHODSPatients taking amlodipine were inspected for the presence of gingival enlargement using Bokenkamp and Bornhorst Index. Periodontal status of the patient was evaluated with Gingival Index, Plaque Index, Probing Pocket Depth and Clinical Attachment Loss. RESULTSIn our study, 5 patients out of 108 patients on amlodipine were clinically diagnosed with enlargement, patients were prescribed amlodipine with a dosage of 2.5 mg and 5 mg. Enlargement was seen in patients prescribed with a dosage of 5 mg/day. Enlargement was found to begin at the interdental papilla and progress to marginal gingiva. The frequency of gingival enlargement induced by Amlodipine was found to be 4.6%. The ratio of enlargement in males and females was 4:1. Plaque index and gingival index were found to be poor in patients with drug-induced enlargement. CONCLUSIONSDentists and/or periodontists should be aware of the complications of certain systemic drugs such as calcium channel blockers so as to diagnose complications or problems like gingival enlargement

7.
Article | IMSEAR | ID: sea-210710

ABSTRACT

The prevalence of hypertension, based on the Indonesian Basic Health Research 2018, was 34.1%. Hypertensivepatients usually show a low quality of life (QoL) due to their lifelong drug dependence. This cross-sectional study wasconducted to determine the QoL of adult hypertensive patients treated with a single calcium channel blocker (CCB)and combination of CCB and angiotensin receptor blocker (ARB) at a primary referral hospital in West Java duringDecember 2018–February 2019. The QoL of the patients was determined using the Indonesian validated Euroqol 5dimensions 5 level and Euroqol visual analog scale questionnaires. 83 adult hypertensive outpatients were recruitedand agreed to participate in this study. Of the 83 hypertensive patients, 44.6% were being treated with a single CCBand 55.4% were being given the combination of CCB and ARB. The characteristics of the patients were as follows:the age was 51 ± 1.04 years, 71.3% were female, 84.3% were married, 66.2% never undertook physical activity, dailydrugs consumed 4 ± 0.19 items, and the duration of hypertensive therapy was 20 ± 3.3 months. Most of the patientsindicated problems in the area of pain and anxiety. The hypertensive patients treated with a combination of nifedipineand candesartan indicated the best QoL, whereas the lowest QoL was found in patients treated with a combination ofnifedipine and valsartan.

8.
Journal of International Pharmaceutical Research ; (6): 496-501, 2020.
Article in Chinese | WPRIM | ID: wpr-845152

ABSTRACT

Tetrandrine(TET)is a bisbenzyl isoquinoline alkaloid extracted from the plant Stephania tetrandra. TET is one of the important active ingredients of S.tetrandra, showing pharmacological effects mainly on the circulatory, respiratory and locomotor systems, such as the anti- inflammatory, anti-tumor, anti-arrhythmia, anti-hypertensive, anti-silicosis and fibrosis effect, and thus has a high clinical application value. This article reviews research achievements of the pharmacological effects, action mechanisms, dosage forms and clinical applications of TET, in order to provide reference for related research.

9.
China Journal of Chinese Materia Medica ; (24): 5093-5102, 2020.
Article in Chinese | WPRIM | ID: wpr-878797

ABSTRACT

To evaluate the efficacy and safety of Yangxue Qingnao Granules alone or combined with calcium channel blocker in treatment of migraine. In this study, four Chinese databases(CNKI, VIP, WanFang, CBM), three English databases(Cochrane Library, EMbase, Medline) and clinical trials registration center(ClinicalTrials.gov) were retrieved. The retrieval time was from the establishment of each database to January 8, 2020. According to the set inclusion criteria and exclusion criteria,the randomized controlled trial(RCT) of Yangxue Qingnao Granules alone or combined with calcium channel blocker was selected. The "Cochrane bias risk assessment" tool was used to evaluate the quality of the included studies. RevMan 5.3 was used to conduct Meta-analysis of the included studies and grade system was used to evaluate the evidence quality of the outcome indicators. A total of 583 documents were retrieved and finally included in 23 studies, with a total sample size of 2 308 cases, 1 171 cases in the treatment group and 1 137 cases in the control group. The overall quality of the research included was not high. Meta-analysis showed that,(1)in terms of effective rate, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(RR=1.24, 95%CI[1.17, 1.32], P<0.000 01), and there was no significant difference between Yangxue Qingnao Granules and calcium channel blocker(RR=1.36, 95%CI[0.91, 2.03], P=0.14).(2)In terms of reducing headache frequency, when the unit of headache frequency was times per month, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-1.39, 95%CI[-1.83,-0.95], P<0.000 01), when the unit of headache frequency was times daily, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-2.08, 95%CI[-2.34,-1.82], P<0.000 01).(3)In terms of headache intensity, when headache intensity was scored by pain intensity, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-0.70, 95%CI[-0.81,-0.59], P<0.000 01), when headache intensity was scored by VAS score, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(MD=-1.59, 95%CI[-2.13,-1.06], P<0.000 01).(4)In terms of reducing headache duration, Yangxue Qingnao Granules combined with calcium channel blocker was better than calcium channel blocker(SMD=-3.13, 95%CI[-4.12,-2.15], P<0.000 01). GRADE system showed that the evidence level of the above outcome indicators was low and extremely low. Twelve cases of adverse reactions were reported, all of which were mild. The results showed that the combination of Yang-xue Qingnao Granules can improve the effective rate, reduce the headache frequency, the headache intensity and the headache duration, and had good safety and low incidence of adverse reactions compared with the single calcium channel blocker. However, there was no difference in the effective rate between Yangxue Qingnao Granules alone and calcium channel blocker. In view of the low quality of this study, which affects the reliability of the conclusion, it is necessary to use the conclusion of this study carefully, and more high-quality randomized controlled trials are needed to further verify in the future.


Subject(s)
Humans , Drugs, Chinese Herbal/adverse effects , Migraine Disorders/drug therapy , Reproducibility of Results
10.
Bol. latinoam. Caribe plantas med. aromát ; 18(2): 204-222, mar. 2019. ilus
Article in English | LILACS | ID: biblio-1007819

ABSTRACT

To explore the mechanistic basis behind smooth muscle relaxant prospective of Bismarckia nobilis in gastrointestinal, respiratory and cardiovascular ailments. The methanolic extract of B. nobilis and sub-fractions have been evaluated in vitro rabbit isolated tissues, in vivo castor oil-induced diarrhea in rats and charcoal meal activity in mice. The B. nobilis extract relaxed spontaneous and K+(80 mM)- induced contractions in rabbit isolated jejunum preparations, CCh (1 µM) and K+ (80 mM)-induced contractions in tracheal and bladder preparations, PE (1 µM) and K+ (80 mM)-induced concentrations in aorta preparations, likewise verapamil. Spasmolytic activity of dichloromethane fraction is stronger as compared to aqueous fraction. In vivo castor oil-induced diarrhea in rats and charcoal meal activity in mice further supported spasmolytic activity. B. nobilis extract possess anti-spasmodic, anti-diarrheal, airway relaxant and vasodilator activities possible mediated through calcium channel blocking mechanism, justifying therapeutic utility of B. nobilis in diarrhea, asthma and hypertension.


El objetivo de trabajo fue explorar el mecanismo de acción relacionado con el efecto relajante del músculo liso inducido por Bismarckia nobilis (B. nobilis) en enfermedades gastrointestinales, respiratorias y cardiovasculares. El extracto metanólico de B. nobilis y subfracciones fue evaluado in vitro en tejidos aislados de conejos. Además se evaluó diarrea in vivo inducida con aceite de ricino en ratas y la actividad de harina de carbón vegetal en ratones. El extracto de B. nobilis relajó tanto las contracciones espontáneas como las inducidas por K+(80 mM) en preparaciones de yeyuno aisladas de conejos, las contracciones inducidas por PE (1 µM) y K+(80 mM) inducidas en preparaciones de aorta; de manera similar a verapamilo. La actividad espasmolítica de la fracción de diclorometano es más potente en comparación con la fracción acuosa. La diarrea inducida in vivo por el aceite de ricino en ratas y la actividad de la harina de carbón vegetal en ratones apoyaron aún más la actividad espasmolítica. El extracto de B. nobilis posee actividades antiespasmódicas, antidiarreicas, relajantes de las vías respiratorias y vasodilatadoras, posibles a través del mecanismo de bloqueo de los canales de calcio, lo que justifica la utilidad terapéutica de B. nobilis en la diarrea, el asma y la hipertensión.


Subject(s)
Animals , Rabbits , Rats , Plant Extracts/pharmacology , Anti-Asthmatic Agents/pharmacology , Arecaceae , Antidiarrheals/pharmacology , Antihypertensive Agents/pharmacology , Aorta/drug effects , Asthma/metabolism , Trachea/drug effects , Calcium Channel Blockers/pharmacology , Diarrhea/metabolism , Methanol , Hypotension/metabolism , Jejunum/drug effects , Muscle Relaxation/drug effects , Muscle, Smooth/drug effects
11.
China Pharmacy ; (12): 2563-2570, 2019.
Article in Chinese | WPRIM | ID: wpr-817278

ABSTRACT

OBJECTIVE: To systematically review therapeutic efficacy and safety of mirtazapine combined with selective calcium channel blocker (SCCB) in the treatment of irritable bowel syndrome (IBS), and provide evidence-based reference for clinical medication. METHODS: Retrieved from the Cochrane Library, PubMed, Embase, Medline, CNKI, VIP and Wanfang database, randomized controlled trials (RCTs) about mirtazapine combined with SCCB (trial group) versus SCCB (control group) for IBS were collected. After literature screening and data extraction, quality evaluation was performed by using Cochrane system evaluator manual 5.1.0 recommend bias risk evaluation tool. Meta-analysis was performed by using Stata 14.0 software. RESULTS: A total of 14 RCTs involving 1 005 patients were included. The results of Meta-analysis showed that the total response rate [RR=1.34,95%CI(1.25,1.44),P<0.001],neuropeptide-Y level after treatment [SMD=0.77,95%CI(0.49,1.05),P<0.001], response rate of abdominal pain therapy [RR=1.32,95%CI(1.06,1.66),P=0.014] and response rate of treatment for abnormal stool characteristics [RR=1.75,95%CI(1.36,2.27), P<0.001] were significantly higher than control group; the scores of depression scale after treatment [SMD=-1.87, 95%CI (-2.35, -1.39), P<0.001], anxiety scale after treatment [SMD=-2.25, 95%CI (-3.35, -1.15), P<0.001], abdominal pain symptom score after treatment [SMD=-7.41, 95%CI  (-8.30,-6.51), P<0.001], diarrhea symptom score after treatment [SMD=-6.39, 95%CI (-7.96,-4.81), P<0.001] were significantly lower than those of the control group. There were no statistical significance in response rate of abdominal distension therapy [RR=1.07,95%CI(0.90,1.28),P=0.421] and response rate of abnormal defecation therapy [RR=1.05,95%CI(0.88,1.26),P=0.588], the incidence of abdominal pain [RR=0.45,95%CI(0.11,1.97), P=0.291] and exhaustion [RR=5.00,95%CI(0.60,41.79),P=0.137] between 2 groups. CONCLUSIONS: Mirtazapine combined with SCCB can significantly improve therapeutic efficacy of IBS patients, promote clinical symptoms, but do not increase the occurrence of ADR as abdominal pain and exhaustion.

12.
World Journal of Emergency Medicine ; (4): 55-58, 2019.
Article in English | WPRIM | ID: wpr-787591

ABSTRACT

@#Calcium channel blocker overdoses are often fatal despite standard treatment. Methylene blue is a novel adjunct that should be considered in refractory cases. Currently accepted therapeutic modalities include intravenous fluids, calcium, vasopressors and high-dose insulin euglycemic therapy, however shock may persist despite these treatment options.[1]

13.
Asian Pacific Journal of Tropical Medicine ; (12): 473-479, 2018.
Article in English | WPRIM | ID: wpr-825872

ABSTRACT

Objective:To explore the antihypertensive effect of extracts from the leaves of Hedera helix (H. helix) on normotensive and hypertensive rats in-vivo followed by vasodilatory studies in-vitro.Methods:The crude methanolic extract was prepared and the activity directed fractionation was carried out. Spectrophotometric analysis of total phenolic and flavonoid content was also done. HPLC analysis was performed for the detection of hederacoside C. In-vivo blood pressure study was carried out in normotensive and high salt-induced hypertensive Sprague-Dawley rats. Isolated aortic tissues from rat and rabbit were used for in-vitro studies. The effects were recorded and analyzed through PowerLab data acquisition system.Results:Crude extract of H. helix (1-30 mg/kg) decreased blood pressure to greater extent in high salt-induced hypertensive rats in-vivo compared to the normotensive [Max. fall (58.59±0.02) mmHg vs. (67.53±3.07) mmHg]. The n-hexane, chloroform, ethyl acetate and aqueous fractions were also checked. These fractions were more effective in hypertensive rats. Aqueous fraction was more potent and n-hexane the least. In isolated rat aortic rings precontracted with phenylephrine, crude extract induced endothelium-dependent effect. The endothelium-dependent component of vasodilatory effect was ablated with L-NAME, and denudation of endothelium. The aqueous fraction was most potent vasodilator. In aortic rings from hypertensive rats, extract and fractions produced partial endothelium-independent effect which was not affected by pretreatment with L-NAME, indicating endothelium dysfunction in the hypertensive rats and suggesting additional vasodilatory mechanisms. In rabbit aorta, the extract and fractions also inhibited phenylephrine and high KConclusions:Our findings indicate that extract and fractions of H. helix are antihypertensive remedies, which is the outcome of vasodilatory effect. This vasodilatory effect is mediated through nitric oxide and Ca

14.
Asian Pacific Journal of Tropical Medicine ; (12): 473-479, 2018.
Article in Chinese | WPRIM | ID: wpr-972436

ABSTRACT

Objective: To explore the antihypertensive effect of extracts from the leaves of Hedera helix (H. helix) on normotensive and hypertensive rats in-vivo followed by vasodilatory studies in-vitro. Methods: The crude methanolic extract was prepared and the activity directed fractionation was carried out. Spectrophotometric analysis of total phenolic and flavonoid content was also done. HPLC analysis was performed for the detection of hederacoside C. In-vivo blood pressure study was carried out in normotensive and high salt-induced hypertensive Sprague-Dawley rats. Isolated aortic tissues from rat and rabbit were used for in-vitro studies. The effects were recorded and analyzed through PowerLab data acquisition system. Results: Crude extract of H. helix (1-30 mg/kg) decreased blood pressure to greater extent in high salt-induced hypertensive rats in-vivo compared to the normotensive [Max. fall (58.59±0.02) mmHg vs. (67.53±3.07) mmHg]. The n-hexane, chloroform, ethyl acetate and aqueous fractions were also checked. These fractions were more effective in hypertensive rats. Aqueous fraction was more potent and n-hexane the least. In isolated rat aortic rings precontracted with phenylephrine, crude extract induced endothelium-dependent effect. The endothelium-dependent component of vasodilatory effect was ablated with L-NAME, and denudation of endothelium. The aqueous fraction was most potent vasodilator. In aortic rings from hypertensive rats, extract and fractions produced partial endothelium-independent effect which was not affected by pretreatment with L-NAME, indicating endothelium dysfunction in the hypertensive rats and suggesting additional vasodilatory mechanisms. In rabbit aorta, the extract and fractions also inhibited phenylephrine and high K

15.
Chinese Pharmacological Bulletin ; (12): 90-94, 2017.
Article in Chinese | WPRIM | ID: wpr-509172

ABSTRACT

Aim To construct 3 D structure model of cardiac Cav1.2 channel and check its accuracy and re-liability.Methods Homology model of Cav1.2 chan-nel α1 subunit was constructed using SWISS-MODEL server.The model was submitted to an online testing server built by University of California and scored by it.The binding of Cav1.2 channel with blocker or drug was simulated by MOE software molecular docking pro-gram to check the model′s accuracy and reliability.Re-sults Both the target sequence Cav1.2 α1 C and the template sequence Cav1.1 α1 S searched by SWISS-MODEL server belonged to L-type Ca2+channel.Since the homology was 7 1.5% revealed by sequence align-ment,homology modeling was performed using automa-ted mode.L-type Ca2+ channel blockers Verapamil, Nifedipine and Diltiazem could bind to the 3 D structure model of Cav1.2 channel,while sodium channel bloc-ker TTX could not.Furthermore,active ingredient of traditional Chinese drug Praeruptorin A and Berberine could also bind to the 3D structure model of Cav1.2 channel.Conclusion The 3 D structure model of Cav1.2 channel was constructed successfully,which provides reliable materials for further studies and estab-lishes the foundation for the application of homology modeling in the study of 3 D structure prediction of ion channels.

16.
Journal of the Korean Neurological Association ; : 62-64, 2016.
Article in Korean | WPRIM | ID: wpr-133769

ABSTRACT

No abstract available.


Subject(s)
Amaurosis Fugax , Retinaldehyde
17.
Journal of the Korean Neurological Association ; : 62-64, 2016.
Article in Korean | WPRIM | ID: wpr-133768

ABSTRACT

No abstract available.


Subject(s)
Amaurosis Fugax , Retinaldehyde
18.
Korean Journal of Clinical Pharmacy ; : 213-219, 2016.
Article in Korean | WPRIM | ID: wpr-62526

ABSTRACT

OBJECTIVE: Although guideline recommends beta blockers (BBs) as first line antianginal agent and calcium channel blockers (CCBs) as alternatives after percutaneous coronary intervention (PCI), the prescription patterns in real practice are not in accordance with the guideline. We aimed to investigate the prescribing patterns of primary antianginal drug and relating factors in patients who underwent PCI. METHODS: Patients who have undergone PCI without myocardial infarction (MI) from November 2012 to June 2014 and followed up at least one year in a tertiary teaching hospital were included. Prescribing patterns of primary antianginal drug before, at the time of, and one year after PCI were described. Factors affecting drug selection, and their relationship with incidence of clinical outcomes defined as MI and repeated PCI, unscheduled admission or visit related with heart problem were analyzed with multivariate logistic regression. RESULTS: A total of 506 patients were included and as primary antianginal drugs, BB, CCB, and both were prescribed in 32.2%, 24.5%, and 17.8% of patients, respectively. Also, neither BB nor CCB was prescribed at the time of PCI in 25.5% of patients. Compared with BB, CCBs were more likely prescribed in patients who had hypertension (Odds Ratio, OR 2.18, 95% confidence interval, CI 1.16-4.07), use of same class before PCI (OR 7.18, 3.37-15.2) and concomitant angiotensin receptor blocker (ARB) use (OR, 1.92, 95% CI 1.10-3.33). Incidence of clinical outcomes were not significantly greater in patients who prescribed CCB compared with BB at the time of PCI (aOR 1.32, CI 0.65-2.68). CONCLUSION: This study demonstrated that half of the patients who underwent PCI were prescribed BB. CCB were favored in patients with hypertension, use of same class before PCI, and concomitant ARB use. Significant difference in clinical outcome was not observed between BB and CCB selection as primary antianginal drug.


Subject(s)
Humans , Angiotensins , Calcium Channel Blockers , Calcium Channels , Calcium , Heart , Hospitals, Teaching , Hypertension , Incidence , Logistic Models , Myocardial Infarction , Percutaneous Coronary Intervention , Prescriptions
19.
Yeungnam University Journal of Medicine ; : 17-21, 2015.
Article in Korean | WPRIM | ID: wpr-85005

ABSTRACT

Amlodipine, a calcium channel blocker of the dihydropyridine group, is commonly used in management of hypertension, angina, and myocardial infarction. Amlodipine overdose, characterized by severe hypotension, arrythmias, and pulmonary edema, has seldom been reported in Korean literature. We report on a fatal case of amlodipine intoxication with complications including rhabdomyolysis and oliguric acute kidney injury. A 70-year-old woman with a medical history of hypertension was presented at the author's hospital 6 hours after ingestion of 50 amlodipine (norvasc) tablets (total dosage 250 mg) in an attempted suicide. Her laboratory tests showed a serum creatinine level of 2.5 mg/dL, with elevated serum creatine phosphokinase and myoglobin. The patient was initially treated with fluids, alkali, calcium gluconate, glucagon, and vasopressors without a hemodynamic effect. High-dose insulin therapy was also started with a bolus injection of regular insulin (RI), followed by continuous infusion of RI and 50% dextrose with water. Despite intensive treatment including insulin therapy, inotropics, mechanical ventilation, and continuous venovenous hemodiafiltration, the patient died of refractory shock and cardiac arrest with no signs of renal recovery 116 hours after her hospital admission.


Subject(s)
Aged , Female , Humans , Acute Kidney Injury , Alkalies , Amlodipine , Arrhythmias, Cardiac , Calcium Channels , Calcium Gluconate , Creatine Kinase , Creatinine , Eating , Glucagon , Glucose , Heart Arrest , Hemodiafiltration , Hemodynamics , Hypertension , Hypotension , Insulin , Myocardial Infarction , Myoglobin , Pulmonary Edema , Respiration, Artificial , Rhabdomyolysis , Shock , Suicide, Attempted , Tablets , Water
20.
Article | IMSEAR | ID: sea-184645

ABSTRACT

Background and Objectives: Many studies in recent years have focused attention on identification of risk factors associated with stroke. However, most of these studies have been conducted in the developed countries. Only few studies have been conducted in Nepal. So the present study has been undertaken with the aim of determining the risk factors and management pattern of stroke and makes the people aware of those factors. Material and Methods: It is a descriptive prospective study conducted with 50 consecutive patients who presented in medicine and emergency department at Universal College of Medical Science, Bhairahawa, Nepal from December 2009 to July 2010. Data were collected using a standard questionnaire and encounter form after receiving a verbal consent from the patient. The collected data were coded, tabulated and analyzed using SPSS version- 16. Results: The present study showed that 56% of stroke patients were male. Hemorrhagic stroke (60%) was more than the ischemic stroke (40%).The age was common non modifiable risk factor. The common–modifiable risk factors were hypertension (86%), alcohol consumption (74%) and smoking (56%). Calcium channel blocker (44.18%) and combination of it with Diuretic (18.60%) and ACE inhibitors (20.93%) were the commonly prescribed drugs for lowering blood pressure. Prescribed drugs therapy and lifestyle modification improved the health condition of patients (80%). The non compliance to the drugs was due to multiple dosages (51.52%), side effects (18.18%) and forgetfulness (18.18%). Conclusion: Finding of this study will be helpful for the practitioners as well as researcher in the future. Practitioners can make people aware on the risk factors and preventive measures of the stroke. Researchers will be helped by knowing the commonest risk factors of stroke and its management pattern.

SELECTION OF CITATIONS
SEARCH DETAIL